Skip to main content
OpenTrials
Completed

NCT Number: NCT07481682

Impact of Inhaled Tranexamic Acid in Pulmonary Hemorrhage in Pediatric Intensive Care Unit

This study aimed to detect the impact of inhaled Tranexamic acid® in pulmonary hemorrhage in pediatric intensive care unit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tranexamic Acid Intensive Care Unit Pediatric Pulmonary Hemorrhage

Age range

1 month–216 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tanta University

Tanta, El-Gharbia, 31527, Egypt

About this study

Pulmonary hemorrhage, often manifested as hemoptysis, can be a severe and life-threatening condition.

Tranexamic acid (TXA)® is a lysine analog that prevents the conversion of plasminogen to plasmin and inhibits plasmin's binding to fibrin, stabilizing the fibrin matrix and reducing bleeding.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age from 1 to 216 months.
  • Both sexes.
  • Patients with pulmonary hemorrhage.

Exclusion criteria

  • Disseminated Intravascular Coagulation (DIC).
  • Laryngeal oedema.
  • Laryngeal web.
  • Contraindications to tranexamic acid include arterial thrombosis, pre-existing coagulopathy, or oral anticoagulant treatment.
  • Patients with traumatic lesions such as hemothorax.

Treatment and study plan

Tranexamic acid + conventional therapy.

Drug

Patients received inhaled or endotracheally instilled Tranexamic acid (TXA) in addition to conventional therapy.

Tranexamic Acid

Drug

Patients received conventional systemic Tranexamic acid (TXA) alone.

Primary outcomes

  1. Cessation of pulmonary hemorrhage

    Time frame: 48 hours of starting inhaled tranexamic acid

    The cessation of pulmonary hemorrhage within 48 hours of starting inhaled tranexamic acid was recorded.

  2. Incidence of adverse effects

    Time frame: 48 hours of starting inhaled tranexamic acid

    Incidence of adverse effects was recorded.

Secondary outcomes

  1. In-hospital mortality

    Time frame: 48 hours of starting inhaled tranexamic acid

    Incidence of in-hospital mortality was recorded.

  2. Length of hospital stay

    Time frame: Till the discharge from the hospital (Up to 2 weeks)

    Length of hospital stay was recorded from the admission till the discharge from the hospital.

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Mar 19, 2026
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.